Relmada Therapeutics
RLMD
126 hedge funds and large institutions have $694M invested in Relmada Therapeutics in 2026 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 23 closing their positions.
68,500% more call options, than puts
Call options by funds: $2.06M | Put options by funds: $3K
104% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 23
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
22% more funds holding
Funds holding: 103 → 126 (+23)
18% more capital invested
Capital invested by funds: $589M → $694M (+$105M)
14.79% more ownership
Funds ownership: 80.77% → 95.56% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$42.9M |
| 2 |
JHC
Jones Hill Capital
New York
|
+$23.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 4 |
VA
VR Adviser
New York
|
+$14M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$15.6M |
| 3 |
Millennium Management
New York
|
-$10.8M |
| 4 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$7.86M |
| 5 |
O
OrbiMed
New York
|
-$7.58M |
RLMD Hedge Fund Activity: Q2 2026 in Review
126 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2026, worth a combined $694M — up 18% from $589M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new RLMD positions and 23 closed out — a net gain of 24 holders — while 36 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $42.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $20.5M sold.
- 126 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2026, up from 103 in Q1 2026.
- Funds reported $694M of Relmada Therapeutics stock for Q2 2026, up 18% quarter-over-quarter.
- 47 funds opened new Relmada Therapeutics positions in Q2 2026 and 23 closed out, a net change of +24 holders.
- The largest Relmada Therapeutics buyer in Q2 2026 was BlackRock, an estimated $42.9M added.
- The largest Relmada Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $20.5M sold.
Based on aggregated 13F filings for Q2 2026.